Financial Performance Overview

  • Q2 FY27 Consolidated Revenue: ₹17,018 million (9% YoY decline)
  • Gross Margin: 49%
  • EBITDA Margin: 14%
  • Operating Cash Flow: ₹9.1 billion (vs. ₹2.3 billion YoY)
  • Net Cash Position: ₹36 billion
  • Net Working Capital: Reduced by 18 days, releasing ₹298 crores cash

Business Segment Performance

Ag Chem Exports:

  • Revenue declined 18% YoY
  • Volume decline: 3-4%
  • Pricing pressure: 13-14%
  • New molecules contribution: 16-18% of export business
  • Order book position: USD 1.25 billion
  • Contract assets: ~₹700 crore (stable)

Domestic Agri Business:

  • Revenue growth: 19% YoY
  • Biologicals portfolio growth: 45% YoY
  • Biologicals contribution: 18% of domestic portfolio

Global Biologicals:

  • Revenue growth: >250% YoY
  • Revenue amount: ~₹60 crores
  • Expansion in Brazil, Mexico, Spain, and US
  • Distribution width increased 3x
  • Expected loss: ~$10+ million for full year

Pharma Business:

  • Revenue growth: 20% YoY
  • Revenue amount: ~₹75 crores
  • Target: ₹500-600 crore revenue with EBITDA breakeven in 2-3 years

Key Developments

Pioxazon Launch:

  • First new chemical entity (Pioxaniliprole) received registration in India
  • Targets pests in rice, corn, and Bengal gram
  • Regulatory filings progressing in other geographies
  • Expect 2-3 more chemical/biological molecules in global arena in coming years

R&D Investment:

  • Continued investment at 3-4% of revenue
  • 12-year development period for innovation platform

New Business Platforms:

  • Pharma CRDMO: Hyderabad center operational, Lodi QC lab commissioned
  • Electronic/Specialty Chemicals: Udaipur kilo lab operational by year-end
  • Target: $100 million business in 3-4 years for electronic chemicals

Margin Analysis

  • Gross margin moderation due to 5% higher input costs and pricing pressure
  • Core overheads tightly controlled
  • New business development costs increased 6%
  • R&D investment increased 2%
  • Energy costs increased 3%

Management Outlook

  • Expect pressure to continue for next couple of quarters
  • See green shoots by end of next financial year
  • Normalized gross margin target: 48-49% (vs. previous 52-53% guidance)
  • Biologicals business expected to reach inflection point in 2-3 years (EBITDA positive)
  • Capex focus shifting to new growth engines beyond agchem

Q&A Highlights

  • New molecules commercialization: 3 added in Q2
  • Electronic chemicals: Early shoots visible, expect ramp-up next year
  • Pricing strategy: Pragmatic decisions to maintain volume and market share
  • Capacity utilization: Adequate for current needs, no immediate capacity constraints
  • Inorganic growth: Evaluating opportunities across agri, pharma, and specialty sectors